ELISpot for measuring human immune responses to vaccines

References

• Czerkinsky CC, Nilsson LA, Nygren H, Ouchterlony O, Tarkowski A. A solid-phase enzyme-linked immunospot (ELISpot) assay for enumeration of specific antibody-secreting cells. J. Immunol. Methods65(1–2), 109–121 (1983).
   PubMed Web of Science ®Google Scholar
• Jerne NK, Nordin AA. Plaque formation in agar by single antibody-producing cells. Science140(3565), 405 (1963).
   Web of Science ®Google Scholar
• Gronowicz E, Coutinho A, Melchers F. A plaque assay for all cells secreting Ig of a given type or class. Eur. J. Immunol.6(8), 588–590 (1976).
   PubMed Web of Science ®Google Scholar
• Czerkinsky C, Prince SJ, Michalek SM et al. Oral immunization with bacterial antigen induces IgA-secreting cells in peripheral blood in humans. Adv. Exp. Med. Biol.216B, 1709–1719 (1987).
   PubMedGoogle Scholar
• Czerkinsky CC, Tarkowski A, Nilsson LA et al. Reverse enzyme-linked immunospot assay (RELISpot) for the detection of cells secreting immunoreactive substances. J. Immunol. Methods72(2), 489–496 (1984).
   PubMed Web of Science ®Google Scholar
• Taguchi T, McGhee JR, Coffman RL et al. Detection of individual mouse splenic T cells producing IFN-γ and IL-5 using the enzyme-linked immunospot (ELISpot) assay. J. Immunol. Methods128(1), 65–73 (1990).
   PubMed Web of Science ®Google Scholar
• Miyahira Y, Murata K, Rodriguez D et al. Quantification of antigen specific CD8+ T cells using an ELISpot assay. J. Immunol. Methods181(1), 45–54 (1995).
   PubMed Web of Science ®Google Scholar
• Lalvani A, Brookes R, Hambleton S et al. Rapid effector function in CD8+ memory T cells. J. Exp. Med.186(6), 859–865 (1997).
   PubMed Web of Science ®Google Scholar
• Herr W, Protzer U, Lohse AW et al. Quantification of CD8+ T lymphocytes responsive to human immunodeficiency virus (HIV) peptide antigens in HIV-infected patients and seronegative persons at high risk for recent HIV exposure. J. Infect. Dis.178(1), 260–265 (1998).
   PubMed Web of Science ®Google Scholar
• Letsch A, Scheibenbogen C. Quantification and characterization of specific T-cells by antigen-specific cytokine production using ELISpot assay or intracellular cytokine staining. Methods31(2), 143–149 (2003).
   PubMed Web of Science ®Google Scholar
• Schmittel A, Keilholz U, Scheibenbogen C. Evaluation of the interferon-γ ELISpot-assay for quantification of peptide specific T lymphocytes from peripheral blood. J. Immunol. Methods210(2), 167–174 (1997).
   PubMed Web of Science ®Google Scholar
• Godard B, Gazagne A, Gey A et al. Optimization of an elispot assay to detect cytomegalovirus-specific CD8+ T lymphocytes. Hum. Immunol.65(11), 1307–1318 (2004).
   PubMed Web of Science ®Google Scholar
• Hill PC, Brookes RH, Fox A et al. Longitudinal assessment of an ELISpot test for Mycobacterium tuberculosis infection. PLoS Med.4(6), e192 (2007).
   PubMed Web of Science ®Google Scholar
• Kester KE, Cummings JF, Ockenhouse CF et al. Phase 2a trial of 0, 1, and 3 month and 0, 7, and 28 day immunization schedules of malaria vaccine RTS,S/AS02 in malaria-naive adults at the Walter Reed Army Institute of Research. Vaccine26(18), 2191–2202 (2008).
   PubMed Web of Science ®Google Scholar
• Lambotte O, Ferrari G, Moog C et al. Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers. AIDS23(8), 897–906 (2009).
   PubMed Web of Science ®Google Scholar
• Gray CM, Mlotshwa M, Riou C et al. Human immunodeficiency virus-specific γ interferon enzyme-linked immunospot assay responses targeting specific regions of the proteome during primary subtype C infection are poor predictors of the course of viremia and set point. J. Virol.83(1), 470–478 (2009).
   PubMed Web of Science ®Google Scholar
• Calarota SA, Foli A, Maserati R et al. HIV-1-specific T cell precursors with high proliferative capacity correlate with low viremia and high CD4 counts in untreated individuals. J. Immunol.180(9), 5907–5915 (2008).
   PubMed Web of Science ®Google Scholar
• Kenter GG, Welters MJ, Valentijn AR et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N. Engl. J. Med.361(19), 1838–1847 (2009).
   PubMed Web of Science ®Google Scholar
• Kirkwood JM, Lee S, Moschos SJ et al. Immunogenicity and antitumor effects of vaccination with peptide vaccine+/-granulocyte-monocyte colony-stimulating factor and/or IFN-α2b in advanced metastatic melanoma: Eastern Cooperative Oncology Group Phase II Trial E1696. Clin. Cancer Res.15(4), 1443–1451 (2009).
   PubMed Web of Science ®Google Scholar
• Gulley JL, Arlen PM, Madan RA et al. Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. Cancer Immunol. Immunother.59(5), 663–674 (2010).
   PubMed Web of Science ®Google Scholar
• Disis ML, Wallace DR, Gooley TA et al. Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer. J. Clin. Oncol.27(28), 4685–4692 (2009).
   PubMed Web of Science ®Google Scholar
• Shafer-Weaver K, Sayers T, Strobl S et al. The Granzyme B ELISpot assay: an alternative to the 51Cr-release assay for monitoring cell-mediated cytotoxicity. J. Transl. Med.1(1), 14 (2003).
   PubMedGoogle Scholar
• Trinchieri G, Perussia B. Human natural killer cells: biologic and pathologic aspects. Lab. Invest.50(5), 489–513 (1984).
   PubMed Web of Science ®Google Scholar
• Smyth MJ, Trapani JA. Granzymes: exogenous proteinases that induce target cell apoptosis. Immunol. Today16(4), 202–206 (1995).
   PubMedGoogle Scholar
• Finn OJ, Lotze MT. A decade in the life of tumor immunology. Clin. Cancer Res.7(Suppl. 3), 759S–760S (2001).
   PubMed Web of Science ®Google Scholar
• Bleackley RC, Lobe CG, Duggan B et al. The isolation and characterization of a family of serine protease genes expressed in activated cytotoxic T lymphocytes. Immunol. Rev.103, 5–19 (1988).
   PubMed Web of Science ®Google Scholar
• Doherty PC, Christensen JP. Accessing complexity: the dynamics of virus-specific T cell responses. Annu. Rev. Immunol.18, 561–592 (2000).
   PubMed Web of Science ®Google Scholar
• Russell JH, Ley TJ. Lymphocyte-mediated cytotoxicity. Annu. Rev. Immunol.20, 323–370 (2002).
   PubMed Web of Science ®Google Scholar
• Assoian RK, Fleurdelys BE, Stevenson HC et al. Expression and secretion of type β transforming growth factor by activated human macrophages. Proc. Natl Acad. Sci. USA84(17), 6020–6024 (1987).
   PubMed Web of Science ®Google Scholar
• Aung H, Sherman J, Tary-Lehman M, Toossi Z. Analysis of transforming growth factor-beta 1 (TGF-β1) expression in human monocytes infected with Mycobacterium avium at a single cell level by ELISpot assay. J. Immunol. Methods259(1–2), 25–32 (2002).
   PubMed Web of Science ®Google Scholar
• Kabilan L, Andersson G, Lolli F et al. Detection of intracellular expression and secretion of interferon-γ at the single-cell level after activation of human T cells with tetanus toxoid in vitro. Eur. J. Immunol.20(5), 1085–1089 (1990).
   PubMed Web of Science ®Google Scholar
• Hagiwara E, Abbasi F, Mor G, Ishigatsubo Y, Klinman DM. Phenotype and frequency of cells secreting IL-2, IL-4, IL-6, IL-10, IFN and TNF-α in human peripheral blood. Cytokine7(8), 815–822 (1995).
   PubMed Web of Science ®Google Scholar
• Gazagne A, Claret E, Wijdenes J et al. A fluorospot assay to detect single T lymphocytes simultaneously producing multiple cytokines. J. Immunol. Methods283(1–2), 91–98 (2003).
   PubMed Web of Science ®Google Scholar
• Kalogerakou F, Albanidou-Farmaki E, Markopoulos AK, Antoniades DZ. Detection of T cells secreting type 1 and type 2 cytokines in the peripheral blood of patients with oral lichen planus. Hippokratia12(4), 230–235 (2008).
   PubMed Web of Science ®Google Scholar
• Smedman C, Gardlund B, Nihlmark K et al. ELISpot analysis of LPS-stimulated leukocytes: human granulocytes selectively secrete IL-8, MIP-1β and TNF-α. J. Immunol. Methods346(1–2), 1–8 (2009).
   PubMed Web of Science ®Google Scholar
• Zheng X, de Paiva CS, Li DQ, Farley WJ, Pflugfelder SC. Desiccating stress promotion of Th17 differentiation by ocular surface tissues through a dendritic cell-mediated pathway. Invest. Ophthalmol. Vis. Sci.51(6), 3083–3091 (2010).
   PubMed Web of Science ®Google Scholar
• Samaras V, Piperi C, Levidou G et al. Analysis of interleukin (IL)-8 expression in human astrocytomas: associations with IL-6, cyclooxygenase-2, vascular endothelial growth factor, and microvessel morphometry. Hum. Immunol.70(6), 391–397 (2009).
   PubMed Web of Science ®Google Scholar
• Boulet S, Ndongala ML, Peretz Y et al. A dual color ELISpot method for the simultaneous detection of IL-2 and IFN-γ HIV-specific immune responses. J. Immunol. Methods320(1–2), 18–29 (2007).
   PubMed Web of Science ®Google Scholar
• Valor L, Navarro J, Carbone J et al. Immunization with an HIV-1 immunogen induces CD4+ and CD8+ HIV-1-specific polyfunctional responses in patients with chronic HIV-1 infection receiving antiretroviral therapy. Vaccine26(22), 2738–2745 (2008).
   PubMed Web of Science ®Google Scholar
• Darrah PA, Patel DT, De Luca PM et al. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat. Med.13(7), 843–850 (2007).
   PubMed Web of Science ®Google Scholar
• Weinberg A, Zhang L, Brown D et al. Viability and functional activity of cryopreserved mononuclear cells. Clin. Diagn. Lab. Immunol.7(4), 714–716 (2000).
   PubMedGoogle Scholar
• Disis ML, dela Rosa C, Goodell V et al. Maximizing the retention of antigen specific lymphocyte function after cryopreservation. J. Immunol. Methods308(1–2), 13–18 (2006).
   PubMed Web of Science ®Google Scholar
• Mander A, Gouttefangeas C, Ottensmeier C et al. Serum is not required for ex vivo IFN-γ ELISpot: a collaborative study of different protocols from the European CIMT Immunoguiding Program. Cancer Immunol. Immunother.59(4), 619–627 (2010).
   PubMed Web of Science ®Google Scholar
• Janetzki S, Price L, Britten CM et al. Performance of serum-supplemented and serum-free media in IFNγ ELISpot assays for human T cells. Cancer Immunol. Immunother.59(4), 609–618 (2010).
   PubMed Web of Science ®Google Scholar
• Maecker HT, Moon J, Bhatia S et al. Impact of cryopreservation on tetramer, cytokine flow cytometry, and ELISpot. BMC Immunol.6, 17 (2005).
   PubMed Web of Science ®Google Scholar
• Maecker HT, Hassler J, Payne JK et al. Precision and linearity targets for validation of an IFNγ ELISpot, cytokine flow cytometry, and tetramer assay using CMV peptides. BMC Immunol.9, 9 (2008).
   PubMed Web of Science ®Google Scholar
• Zhang W, Caspell R, Karulin AY et al. ELISpot assays provide reproducible results among different laboratories for T-cell immune monitoring – even in hands of ELISpot-inexperienced investigators. J. Immunotoxicol.6(4), 227–234 (2009).
   PubMed Web of Science ®Google Scholar
• Boaz MJ, Hayes P, Tarragona T et al. Concordant proficiency in measurement of T-cell immunity in human immunodeficiency virus vaccine clinical trials by peripheral blood mononuclear cell and enzyme-linked immunospot assays in laboratories from three continents. Clin. Vaccine Immunol.16(2), 147–155 (2009).
   PubMedGoogle Scholar
• Samri A, Durier C, Urrutia A et al. Evaluation of the interlaboratory concordance in quantification of human immunodeficiency virus-specific T cells with a γ interferon enzyme-linked immunospot assay. Clin. Vaccine Immunol.13(6), 684–697 (2006).
   PubMedGoogle Scholar
• Janetzki S, Panageas KS, Ben-Porat L et al. Results and harmonization guidelines from two large-scale international ELISpot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI). Cancer Immunol. Immunother.57(3), 303–315 (2008).
   PubMed Web of Science ®Google Scholar
• Janetzki S, Cox JH, Oden N, Ferrari G. Standardization and validation issues of the ELISpot assay. Methods Mol. Biol.302, 51–86 (2005).
   PubMedGoogle Scholar
• Weinberg A, Song LY, Wilkening CL et al. Optimization of storage and shipment of cryopreserved peripheral blood mononuclear cells from HIV-infected and uninfected individuals for ELISpot assays. J. Immunol. Methods363(1), 42–50 (2010).
   PubMed Web of Science ®Google Scholar
• Kalyuzhny A, Stark S. A simple method to reduce the background and improve well-to-well reproducibility of staining in ELISpot assays. J. Immunol. Methods257(1–2), 93–97 (2001).
   PubMed Web of Science ®Google Scholar
• Moodie Z, Price L, Gouttefangeas C et al. Response definition criteria for ELISpot assays revisited. Cancer Immunol. Immunother.59(10), 1489–1501 (2010).
   PubMed Web of Science ®Google Scholar
• Dubey S, Clair J, Fu TM et al. Detection of HIV vaccine-induced cell-mediated immunity in HIV-seronegative clinical trial participants using an optimized and validated enzyme-linked immunospot assay. J. Acquir. Immune Defic. Syndr.45(1), 20–27 (2007).
   PubMed Web of Science ®Google Scholar
• Pagano M, Gauvreau K. Principles of Biostatistics 2nd Edition. Duxbury Press, Pacific Grove, CA, USA (2000).
   Google Scholar
• Hanekom WA, Dockrell HM, Ottenhoff TH et al. Immunological outcomes of new tuberculosis vaccine trials: WHO panel recommendations. PLoS Med.5(7), e145 (2008).
   PubMed Web of Science ®Google Scholar